StreetInsider.com News Articles

Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026

Wed, 21 Oct 2026 18:30:00 -0400

HOLLISTER, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2026, on Wednesday, November 4, 2026, following the close of market.

Teknova will host a webcast and conference call on Wednesday, November 4, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor

Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026

Wed, 21 Oct 2026 18:30:00 -0400

Teknova will host a webcast and conference call on Wednesday, November 4, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor

Form 8-K Alpha Teknova, Inc. For: Oct 20

Wed, 21 Oct 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20261021/27217034.html

Form 424B5 Alpha Teknova, Inc.

Wed, 21 Oct 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20261021/27216979.html

Teknova prices $40M public offering at $5.00 per share

Tue, 20 Oct 2026 22:30:11 -0400

Alpha Teknova, Inc. (Nasdaq: TKNO), a producer of reagents for life sciences, announced the pricing of an underwritten public offering of 8,000,000 shares of common stock at $5.00 per share, with gross proceeds expected to reach $40 million before deducting underwriting discounts, commissions, and offering expenses.

The Hollister, California-based company has also granted underwriters a 30-day option to purchase up to 1,200,000 additional shares. The offering is expected to close on or about October 22, 2026, subject to customary closing conditions.

Teknova said it intends to use the net proceeds for general corporate purposes, which may include repayment of outstanding debt. The

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

Tue, 20 Oct 2026 22:30:00 -0400

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $40 million. Teknova has also granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

Tue, 20 Oct 2026 22:30:00 -0400

Form 424B5 Alpha Teknova, Inc.

Tue, 20 Oct 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20261020/27210473.html

Teknova reports preliminary Q3 revenue of up to $12.7M, up 21%

Tue, 20 Oct 2026 16:02:43 -0400

Alpha Teknova, Inc. (Nasdaq: TKNO) released preliminary unaudited financial results for the third quarter ended September 30, 2026, estimating revenue between $12.5 million and $12.7 million, representing a 19% to 21% increase compared to the same period in the prior year.

Gross margin for the quarter is estimated at 36.0% to 38.0%, reflecting an expansion of 500 to 700 basis points year-over-year. The company attributed the margin improvement primarily to top-line growth.

Adjusted EBITDA for the quarter is estimated at negative $1.2 million to negative $1.0 million, which the company said represents at least a 25% improvement compared to the same period

Teknova launches public stock offering on Nasdaq

Tue, 20 Oct 2026 16:02:16 -0400

Alpha Teknova, Inc. (Nasdaq: TKNO), a reagent producer based in Hollister, California, announced the commencement of an underwritten public offering of its common stock, according to a company press release.

All shares in the proposed offering will be sold by Teknova. The company also intends to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered. TD Cowen and William Blair are serving as joint book-running managers for the offering.

Teknova said it plans to use net proceeds for general corporate purposes, which may include repayment of outstanding debt. The company also noted it may use

Teknova Announces Proposed Public Offering of Common Stock

Tue, 20 Oct 2026 16:02:00 -0400

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has commenced an underwritten public offering of its common stock. Teknova also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock offered in the offering. All of the shares of common stock to be sold in the proposed offering are to be sold by Teknova. The

Teknova Announces Proposed Public Offering of Common Stock

Tue, 20 Oct 2026 16:02:00 -0400

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has commenced an underwritten public offering of its common stock. Teknova also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock offered in the offering. All of the shares of common stock to be sold in the proposed offering are to be sold by Teknova. The

Teknova Announces Preliminary Third Quarter Financial Results

Tue, 20 Oct 2026 16:01:00 -0400

Set forth below are certain preliminary unaudited financial results for the three months ended September 30, 2026 and as of September 30, 2026:

Revenue for the three months ended September 30, 2026 is estimated to

Teknova Announces Preliminary Third Quarter Financial Results

Tue, 20 Oct 2026 16:01:00 -0400

Set forth below are certain preliminary unaudited financial results for the three months ended September 30, 2026 and as of September 30, 2026:

Revenue for the three months ended September 30, 2026 is estimated to

Alpha Teknova Inc. (TKNO) PT Raised to $11 at TD Cowen

Tue, 13 Oct 2026 09:39:22 -0400

TD Cowen analyst Brendan Smith raised the price target on Alpha Teknova Inc. (NASDAQ: TKNO) to $11.00 (from $7.00) while maintaining a rating.

Teknova and Pluristyx file FDA drug master file for PluriFreeze system

Fri, 02 Oct 2026 16:02:25 -0400

Alpha Teknova, Inc. (Nasdaq: TKNO) and Pluristyx, Inc. announced that Pluristyx is completing a Type II Drug Master File (DMF) for the PluriFreeze™ cryopreservation system for submission to the U.S. Food and Drug Administration.

The DMF will allow drug developers using PluriFreeze during preclinical stages to request a letter of authorization from Pluristyx and cross-reference the file in Investigational New Drug applications and Biologics License Applications. The submission covers chemistry, manufacturing, and controls documentation for the PluriFreeze system.

"The PluriFreeze DMF gives advanced therapy developers more to build on than strong product performance: a documented regulatory position for their cryopreservation system, ready

Teknova and Pluristyx file FDA drug master file for PluriFreeze system

Fri, 02 Oct 2026 16:02:25 -0400

"The PluriFreeze DMF gives advanced therapy developers more to build on than strong product performance: a documented regulatory position for their cryopreservation system, ready

Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System

Fri, 02 Oct 2026 16:01:00 -0400

Developers of advanced therapies using PluriFreeze during preclinical stages can seamlessly scale to clinical manufacturing and cross-reference the Drug Master File in FDA submissions

HOLLISTER, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc. (“Pluristyx”), today announced that Pluristyx is completing a Type II Drug Master File (DMF) for the PluriFreeze™ cryopreservation system for submission to the U.S. Food and Drug Administration (FDA). The DMF will support drug makers seeking to incorporate PluriFreeze into their clinical development and manufacturing programs. Teknova is a leading producer of critical reagents for the discovery,

Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System

Fri, 02 Oct 2026 16:01:00 -0400

Developers of advanced therapies using PluriFreeze during preclinical stages can seamlessly scale to clinical manufacturing and cross-reference the Drug Master File in FDA submissions

Jefferies Starts Alpha Teknova Inc. (TKNO) at Buy

Thu, 17 Sep 2026 02:49:12 -0400

Jefferies analyst Matthew Stanton initiates coverage on Alpha Teknova Inc. (NASDAQ: TKNO) with a Buy rating and a price target of $9.00.

The analyst comments: “TKNO is emerging player offering RUO and GMP products to variety of attractive life science and diagnostics applications. We see plenty of growth ahead, with upside tied to biotech funding (2H26 and beyond), recent commercial investment (early '27) and clinical pipeline (2027+). This demand will support significant GM ramp (from ~40% today to 55-60%), with upside to both '27 (+100bps) & '28 (+300-400bps), in our view. Initiate at Buy, $9 PT = 9x '27E EV/ revs.

TKNO's

Jefferies Starts Alpha Teknova Inc. (TKNO) at Buy

Thu, 17 Sep 2026 02:49:12 -0400

Jefferies analyst Matthew Stanton initiates coverage on Alpha Teknova Inc. (NASDAQ: TKNO) with a Buy rating and a price target of $9.00.

TKNO's

Teknova launches Fill-Tek dispensing system for single-use bag filling

Wed, 16 Sep 2026 17:31:16 -0400

Alpha Teknova, Inc. (Nasdaq: TKNO) introduced the Fill-Tek™ Dispensing System, a proprietary single-use bag dispensing capability that allows customers to order custom reagent combinations across multiple bag sizes and quantities as a single lot with one Certificate of Analysis.

According to a company press release, Fill-Tek removes per-bag-size minimums associated with fixed manifold designs by using validated aseptic welds to connect a customer's specified combination of single-use bags to a dispensing vessel, filling them from a single batch through a single filter.

Customers can specify bag sizes ranging from 250 mL to 200 L, and customize fill volume, number, size, and sequence

Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling

Wed, 16 Sep 2026 17:30:00 -0400

Available now, this new proprietary dispensing capability lets customers order the exact single-use bag sizes and quantities their process requires, released as a single lot with one Certificate of Analysis, with no added turnaround time

HOLLISTER, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today introduced the Fill-Tek™ Dispensing System. Fill-Tek is a proprietary single-use bag dispensing capability that fills an entire custom reagent order across multiple bag sizes and quantities as

Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling

Wed, 16 Sep 2026 17:30:00 -0400

BTIG Upgrades Alpha Teknova Inc. (TKNO) to Buy following earnings

Tue, 11 Aug 2026 05:48:19 -0400

BTIG analyst Mark Massaro upgraded Alpha Teknova Inc. (NASDAQ: TKNO) from Neutral to Buy with a price target of $8.00.

The analyst comments "We upgrade Alpha Teknova from a Neutral to a Buy rating and establish a price target of $8.00/share. TKNO delivered a top- and bottom-line beat in Q2'26, and raised its 2026 revenue guidance on improving fundamentals in its business on the back of an improving funding environment in life sciences. Unlike in recent prior years, TKNO is now driving broad-based double-digit revenue growth across both of its key segments at a rate of +18% Y/Y, and we think